COVID-19 Adverse Outcomes in Immunocompromised Patients

International Journal of Cancer Management, Journal Year: 2023, Volume and Issue: 16(1)

Published: March 5, 2023

Background: Coronavirus disease 2019 (COVID-19) is a devastating viral pandemic infecting millions of people with wide range symptoms from fever to death. It has been suggested that immunocompromised patients are at higher risk severe disease, poor clinical outcomes, and mortality. However, these patients’ factors COVID-19-related outcomes not well characterized. Objectives: We evaluated the among ranging solid tumors, hematological malignancies, HIV autoimmune transplant recipients who received immunosuppressive agents. also aimed finding related mortality COVID-19. Methods: This cross-sectional study was conducted in Khansari Hospital, Iran between March November 2021. included nasal swab positive SARS-CoV-2 polymerase chain reaction (PCR) results study. Patient including hospitalization ward rate, were assessed till three months after COVID-19 infection all patients. Moreover, relation rate analyzed Results: A total number 74 hematologic diseases, acquired immunodeficiencies, solid-organ Results indicated male gender ICU significantly increase risk. Surprisingly, chemotherapy associated lower Conclusions: Identifying can improve decision-making on cancer management during infection. further large cohort would be required identify relating rates

Language: Английский

---

SARS-CoV-2 and HIV: Impact on Pulmonary Epithelial Cells

Life, Journal Year: 2022, Volume and Issue: 12(9), P. 1317 - 1317

Published: Aug. 26, 2022

The SARS-CoV-2 pandemic provides a natural opportunity for the collision of coronavirus disease-2019 (COVID-19) with chronic infections, which place numerous individuals at high risk severe COVID-19. Infection Human Immunodeficiency Virus (HIV), global epidemic, remains major public health concern. Whether prior HIV+ status exacerbates COVID-19 warrants investigation. Herein, we characterized impact in human bronchial epithelial cells (HBECs) previously exposed to HIV. We optimized air-liquid interface (ALI) cell culture technique allow challenges HIV basolateral surface and spike protein on apical surface, followed by genetic analyses cellular stress/toxicity innate/adaptive immune responses. Our results suggest that IL-10 pathway was consistently activated HBECs treated spike, HIV, or combination. Recombinant elicited cytokine storms while different signaling pathways. HIV-treated could no longer activate NF-kB, pro-inflammatory TRAF-6 ubiquitination nor RIP1 signaling. Combinations increased gene expression activation endoplasmic reticulum-phagosome downregulated non-canonical NF-kB pathways are key functional regulatory T RNA Polymerase II transcription. vitro studies infection may not exacerbate Further vivo warranted advance this field.

Language: Английский

---

A case report of COVID-19 associated with AIDS-related pulmonary tuberculosis

Research Square (Research Square), Journal Year: 2022, Volume and Issue: unknown

Published: Dec. 16, 2022

Abstract Patients immunocompromised by HIV or with TB lung disease could be more susceptible to severe COVID-19 infection. The pandemic poses a serious hazard tuberculosis sufferers. A 67-year-old black African house wife an HIV/AIDS diagnosis arrived at the emergency room on September 28, 2022. admitted woman had significant complaints included muscle weakness, loss of weight about 33 pounds during preceding week, headache, and cough. Reduced breath sounds were audible chest auscultation in right middle upper lungs. His electrocardiogram showed sinus tachycardia anterior-lateral lead ST-depression. She two nasopharyngeal swabs for testing, which positive. For first five days her stay hospital, patient needed continuous oxygen delivered through nasal cannula rate four liters per minute, she is still taking ART regimen. treatment, took rifampicin 150 mg, isoniazid 75 pyrazinamide 400 ethambutol 275 mg two-month intensive phase therapy, then four-month phase.

Language: Английский

---

Comparison of clinical, radiological and laboratory findings in discharged and dead patients with COVID-19

Vacunas (English Edition), Journal Year: 2022, Volume and Issue: 23, P. S36 - S43

Published: Sept. 1, 2022

---